Companies / Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics, Inc.
Nasdaq: GLUECIK 1826457BOSTON, MA
Financials
Ownership
85.3M shares outstanding · as of Jul 31, 2026
Ownership
| Insiders | 1.05% | 892,923 |
| Institutions | 85.48% | 72,927,418 |
| Public float | 13.47% | 11,493,060 |
% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.
Insiders 7
View all →| Insider | % of shares | Shares |
|---|---|---|
Warmuth MarkusCEOPresident & CEO · Director | 0.72% | 613,471 |
Townson SharonChief Scientific Officer | 0.08% | 67,845 |
Janku FilipChief Medical Officer | 0.08% | 65,837 |
Champoux JenniferChief Operating Officer | 0.07% | 62,371 |
Nickson PhilipChief Business & Legal Officer | 0.07% | 60,845 |
Dunn EdmundPrincipal Accounting Officer | 0.03% | 22,554 |
Schiff Andrew NDirector | — | — |
Institutional holders 174
View all →| Holder | Value | % of shares |
|---|---|---|
| $165.60M | 8.02% | |
| $120.62M | 9.02% | |
| $90.30M | 4.37% | |
| $73.38M | 5.23% | |
| $72.48M | 5.42% | |
| $71.49M | 5.09% | |
| $68.72M | 5.14% | |
| $52.68M | 3.94% | |
| $50.91M | 3.81% | |
| $25.35M | 1.81% |
Activity
Jun 30, 2026View all →
InsidersInstitutions
Who's accumulating and trimming this stock (13F).| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Q2 2026 as of | BlackRock, Inc. 13F manager | Add | — | $64.42M | +2.7M +63.66% | 6,843,087 8.02% of shares | high |
| Q2 2026 as of | State Street Corporation 13F manager | Add | — | $39.30M | +1.6M +77.06% | 3,731,416 4.37% of shares | medium |
| Q1 2026 as of | Marshall Wace, LLP 13F manager | Add | — | $17.01M | +1.0M +259.29% | 1,433,152 1.68% of shares | medium |
| Q1 2026 as of | Janus Henderson Group PLC 13F manager | New | — | $11.29M | +686K | 685,926 0.80% of shares | medium |
| Q1 2026 as of | Bvf INC/IL 13F manager | Add | — | $10.28M | +625K +16.29% | 4,460,886 5.23% of shares | medium |
| Q2 2026 as of | Alphabet Inc. 13F manager | Trim | — | $-9.01M | -372K -50.00% | 372,474 0.44% of shares | medium |
| Q1 2026 as of | Renaissance Technologies LLC 13F manager | New | — | $6.24M | +379K | 379,100 0.44% of shares | medium |
| Q1 2026 as of | Arrowstreet Capital, Limited Partnership 13F manager | Add | — | $5.59M | +340K +110.54% | 647,739 0.76% of shares | medium |
5%+ ownership events
Schedule 13D / 13G
| Filer | Stance | % of class |
|---|---|---|
| Baker Bros. Advisors LP | Passive13G/A | — |
| Adam Goulburn | Passive13G/A | — |
| Biotechnology Value Fund L P | Passive13G/A | — |
| Baker Bros. Advisors LP | Passive13G/A | — |
Securities
via CUSIP / OpenFIGI
| Symbol | Type | CUSIP |
|---|---|---|
| GLUE | — | 61225M102 |